Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Panacea Or PR Victory? Expedited US ANDAs May Have Limited Impact

This article was originally published in PharmAsia News

Executive Summary

In theory, reviewing US generic applications faster should speed competition; in practice, the FDA's new policy likely won't make too much difference.

You may also be interested in...



Preventing Missing Data Among Concerns In US FDA’s Guidance On COVID-19 Symptom Assessment

Investigators should plan to find the vital status of discontinued patients, guidances states. Participants need frequent reminders to complete PRO instruments, agency recommends.

User Fee Renewal Negotiations Beginning This Week

Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.

After First COVID-19 Vaccine Approval, How Will Other Trials Maintain Placebo Control?

US FDA officials fear comparator arms would be unwieldy for ongoing trials as they consider alternative methods to measure efficacy if placebo controls can't be maintained for the studies of other candidate vaccines once a product is on the market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel